Overview

DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

Status:
Active, not recruiting

Trial end date:
2023-04-01

Target enrollment:

Participant gender:

Summary

This study is designed to compare the anti-tumor activity as well as the safety and efficacy of DS-8201a versus T-DM1 in HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane.

Phase:

Phase 3

Details

Lead Sponsor:

Daiichi Sankyo, Inc.

Collaborators:

AstraZeneca
Daiichi Sankyo Co., Ltd.

Treatments:

Ado-Trastuzumab Emtansine
Camptothecin
Immunoconjugates
Maytansine
Taxane
Trastuzumab